Validation of a New Homogeneous Immunoassay for the Detection of Carisoprodol in Urine
|
|
- Edmund Hill
- 5 years ago
- Views:
Transcription
1 Validation of a New Homogeneous Immunoassay for the Detection of Carisoprodol in Urine Guohong Wang*, Kim Huynh, Rekha Barhate, Warren Rodrigues, Christine Moore, Cynthia Coulter, Michael Vincent, and James Soares Immunalysis Corporation, 829 Towne Center Drive, Pomona, California Abstract The objective of this project was to validate a new high-throughput homogeneous enzyme immunoassay (HEIA) for the rapid detection of carisoprodol in human urine. Carisoprodol (Soma ) and meprobamate are widely prescribed as musculoskeletal pain relief drugs and are listed as one of the 10 most frequently identified drugs associated with DUI cases. Carisoprodol has a short elimination half-life of 1 3 h; however, its major active metabolite, meprobamate, has a longer elimination half-life of 6 17 h. As a result, it is important for an immunoassay to cross-react with both compounds. The advantage of this new assay is that cutoff concentrations can be adjusted between 100 and 500 ng/ml. The reportable range was 25 to 1000 ng/ml for carisoprodol and 50 to 10,000 ng/ml for meprobamate. The intraday coefficient of variation (% CV) for the semi-quantitative assay was less than 1%. The homogeneous assay was validated with a total of 86 urine samples previously analyzed by liquid chromatography tandem mass spectrometry with carisoprodol concentrations ranging from 50 to 10,000 ng/ml. The accuracy was found to be 100% when immunoassay cutoff concentrations of carisoprodol and meprobamate were set at 100 and 1000 ng/ml, respectively. Introduction The popularity of the drug is due to its pain relief and euphoric effect during treatment, increasing the potential for abuse (3,4). The effects of both carisoprodol and meprobamate are similar to those of alcohol, with loss of balance, sedation, and confusion, which is why both of these drugs are on the list of the 10 most identified drugs in DUI cases (5). In addition, these drugs are frequently present in urine specimens collected from chronic pain patients (6). Currently, enzyme-linked immunosorbant assay (ELISA) is the only commercially available screening method for the detection of carisoprodol and meprobamate in urine and blood (7) followed by confirmation methods such as liquid chromatography with mass spectral detection (LC MS MS) (8 10) or gas chromatography mass spectrometry (GC MS) (11,12). For this reason, it is highly desirable to develop a novel high-throughput and sensitive homogeneous enzyme immunoassay screening method to detect both carisoprodol and meprobamate in urine. The ratio between parent drug and metabolite could vary dramatically depending on the matrix employed. The in house antibody was designed for different matrices such as oral fluid, hair, and the like because they require the detection of the parental drug. This assay also can be used to detect a patient taking meprobamate. As the detection time of meprobamate in urine is 2 10 Carisoprodol and meprobamate have been commercially available for over 50 years for the treatment of musculoskeletal pain. Carisoprodol can be metabolized through n-dealkylation reaction to its major active metabolite, meprobamate, and to a lesser extent, by hydroxylation reaction to a hydroxycarisoprodol and hydoxymeprobamate in the liver (Figure 1). Carisoprodol has a short elimination half-life of 1 3 h; however, its major active metabolite, meprobamate, is also a prescribed drug and has a longer elimination half-life of 6 17 h and thus a longer detection time than carisoprodol in urine (1,2). * Author to whom correspondence should be addressed. gwang@immunalysis.com. Figure 1. Chemical structures of carisoprodol and its metabolites. 108 Reproduction (photocopying) of editorial content of this journal is prohibited without publisher s permission.
2 times longer than carisoprodol because of its higher dosage and slower elimination, the new assay has a lower cross-reactivity for meprobamate. In this paper, we report the first homogeneous immunoassay that can simultaneously and rapidly detect both carisoprodol and meprobamate in urine specimens. The detection ranges were determined to be 25 to 1000 ng/ml for carisoprodol and 50 to 10,000 ng/ml for meprobamate. Matrix effects and nonrelated drug interferences were not observed. Experimental Urine specimens Eighty-six clinical urine specimens were collected from outside laboratories that also provided confirmation results. The urine specimens were a combination of negative and positive specimens at an LC MS MS confirmation cutoff of 50 ng/ml for carisoprodol and 500 ng/ml for meprobamate. Apparatus and reagents An Olympus AU400e automatic chemical analyzer was used and was provided by Immunalysis (Pomona, CA). The carisoprodol and meprobamate (1 mg/ml in methanol) drug standards were purchased from Cerilliant (Round Rock, TX). Enzyme reagents and antibody/substrate reagents were provided by Immunalysis; carisoprodol polyclonal antibody and hapten were also provided by Immunalysis. Glucose-6-phosphate dehydrogenase (G6PDH) was purchased from Oriental Yeast (Japan). Drug mixes for cross-reactivity with unrelated drug were all purchased from Discovery Sciences (State College, PA). Preparation of reagent antibody (RA) and reagent enzyme (RE) RA was prepared from in-house-raised polyclonal antibody diluted with 20 mm Tris-hydrochloric acid (Tris-HCl) buffer (ph 6.0) containing 0.05 M nicotinamide adenine dinucleotide (NAD) and 0.5% sodium chloride (NaCl). RE was prepared from in-house carisoprodol-g6pdh conjugate diluted with 0.1 M Tris-HCl buffer (ph 7.8) containing 0.2% bovine serum albumin (BSA) and 0.5 M glucose-6-phosphate (G6P). Principles of homogeneous enzyme immunoassay (HEIA) The HEIA technique is based on an immunoassay format in which both the antibody (RA) and enzyme-drug conjugate (RE) are in ready-to-use solution. The assay is performed by mixing the sample with reagents RA and RE and requires no separation step. In the absence of the target analyte in the specimen, enzyme-labeled drug conjugate binds to the antibody and results in decrease of the enzyme (G6PDH) activity; hence, there is lower absorbance at 340 nm. If the target analyte is present in the specimen, it competes with the enzymelabeled drug to bind to a limited amount of specific antibody, that results in more enzyme activity and yield an increased absorbance at 340 nm. Parameters for HEIA. The HEIA was performed on the Olympus AU400e automated chemical analyzer with a 4-µL sample size, 100 µl of RA, and 100 µl of RE. In the automated chemical analyzer, the sample and RA reagent were mixed and incubated for 5 min before the addition of the RE reagent. The absorbance of the enzyme activity was then measured at 340 nm. Assay performance. To validate the assay performance of the HEIA, sensitivity, precision, drug recovery, stability, and specificity were analyzed. To determine the limit of detection (LOD), carisoprodol drug concentrations at 0, 1, 5, 10, and 15 ng/ml were analyzed in replicates of 20 to establish the mean values and standard deviations, and the calculation of the LOD as the mean plus two standard deviations from the zero calibrator. The precision of the assay was determined by preparing carisoprodol calibrators and controls by diluting 1 mg/ml drug standard to concentrations of 0, 50, 75, 100, 125, 200, 500, and 1000 ng/ml, and aliquots were analyzed using the Olympus AU400e automated chemical analyzer. The precision (intraday and interday) was determined by analyzing calibrators and controls for four days, with two runs per day. For the drug recovery, carisoprodol-fortified authentic urine samples were tested against the carisoprodol standard calibration curve. Negative authentic urine was spiked at concentrations of 0, 50, 75, 100, 125, 200, 500, and 1000 ng/ml and analyzed on the Olympus 400e automated chemical analyzer. A stability study was performed on carisoprodol HEIA to determine if the assay performance was stable at 25 C for 21 days. A 200-mL bottle of each carisoprodol G6PDH-conjugate reagent (RE) and carisoprodol antibody reagent (RA) were stored at 25 C unexposed to light for 21 days. The RA and RE were tested at days 1, 3, 7, 14, and 21 to determine if 25 C storage affected the assay performance. A carisoprodol RA and RE stored at 5 C (control) were tested along with the 25 C carisoprodol-g6pdh as a control for the assay performance. To determine specificity, the cross-reactivities of metabolite and commonly used structurally unrelated drugs were analyzed using carisoprodol HEIA. LC MS MS An Agilent Technologies 1200 series LC pump coupled to a 6410 triple-quadrupole MS, operating in positive electrospray mode (ESI) was used for analysis. The LC column was a Zorbax Eclipse XDB-C 18 Rapid Resolution HT ( mm, 1.8 micron). The column temperature was held at 40 C, and the injection volume was 5 μl. The mobile phase consisted of 20 mm ammonium formate (ph 6.4, Solvent A) and methanol (Solvent B). At the beginning of the run, the mobile phase composition was 85% A/15% B at a constant flow rate of 0.7 ml/min. After 4 min, the percentage of solvent B was 100%, and at 5 min, the percentage of B returned to 15%. The equilibration time was 3 min. The gas temperature was 350 C, the gas flow was 10 L/min, and the nebulizer pressure was 50 psi. Nitrogen was used as the collision gas, and the capillary voltage was 4000 V. Two transitions were selected and optimized for carisoprodol and meprobamate. For carisoprodol-d 7, the precursor ion was fragmented to at optimized fragment voltage of 60 V and collision energy of 2 V. For carisoprodol, the precursor ion 109
3 of was fragmented to (quantitative transition) and (qualitative transition) at fragment voltages of 60 V; collision energy of 2 V. For meprobamate, the precursor ion of was fragmented to (quantitative transition) and 97.1 (qualitative transition) at fragment voltages of 60 V; collision energy of 2 V. Each subsequent analysis required the ratio between the quantitative transition and the qualifying transition to be within ±20% of that established by calibration standards in order to meet the criterion for a positive result. Figure 2. Carisoprodol dose-response curve. Table I. Precision at 100 ng/ml Cutoff Concentration Mean Standard (ng/ml) ma/min Deviation CV % Intraday precision (n = 16) 50 ng/ml Calibrator ng/ml (Control LOW) ng/ml Calibrator ng/ml (Control HIGH) ng/ml Calibrator ng/ml Calibrator ng/ml Calibrator Interday precision (n = 64) 50 ng/ml Calibrator ng/ml (Control LOW) ng/ml Calibrator ng/ml (Control HIGH) ng/ml Calibrator ng/ml Calibrator ng/ml Calibrator Table II. Accuracy: Percent Analytical Recovery Actual Measured Carisoprodol Carisoprodol Drug Concentration Concentration Recovery (ng/ml) (ng/ml) (%) Validation (LC MS MS) Calibration of the assay, slope, intercept, and correlation coefficients were calculated using linear regression analysis over the calibration range. Peak-area ratios of the target analyte and the internal standard were calculated using Mass Hunter software (Agilent). The data were fit to a linear leastsquares regression curve with a 1/x weighting and not forced through the origin. The linearity of the assay was established with five calibration points, excluding the drug-free matrix. The limit of quantitation, defined as the lowest concentration detectable with a signal-to-noise ratio of at least 10 for the quantifying ion and retention time within 0.2 min of the calibration standard, was determined to be 5 ng/ml for both carisoprodol and meprobamate. Results and Discussion Evaluation of enzyme activity A carisoprodol calibration curve was generated using carisoprodol-fortified urine at calibration points of 0, 50, 100, 200, 500, and 1000 ng/ml. Carisoprodol drug concentration in the specimen was measured in terms of enzyme activity ( ma/min) in the assay. As shown on the dose-response curve, with an increase in drug concentration in the specimen there was an increase in ma/min or enzyme activity (Figure 2). Sensitivity The LOD of carisoprodol in urine for the homogeneous enzyme immunoassay was based on the minimum carisoprodol concentration required to produce two standard deviations of absorbance change from the negative calibrator. The LOD for carisoprodol was determined to be 5 ng/ml. Precision and drug recovery Intraday and interday precision was determined by analyzing calibrators and controls for 4 days, 2 runs per day, in replicates of 8 [intraday (n = 16), interday (n = 64)]. The percentage CV for intraday rate and interday precision was less than 1% (Table I). A percentage drug recovery calculation was made for each known spiked drug concentration. Carisoprodol drug recovery was above 89% (Table II). Cross-reactivity with carisoprodol metabolites An in-house polyclonal antibody that has a higher crossreactivity for carisoprodol and lower cross-reactivity for meprobamate, because meprobamate is administered in higher 110
4 Table III. Drugs Analyzed for Cross-Reactivity at 10,000 ng/ml: No Interference Detected Structurally Unrelated Drugs Drug Acetaminophen Ethotoin Nortryptyline Acetylsalicylic acid Flunitrazepam Oxycodone Alprazolam Flurazepam Pentazocine d-amphetamine Glutethimide Phenobarbital Aminopyrine Hexobarbital PEMA Amitryptyline Ibuprofen Phencyclidine (PCP) Ampicillin Imipramine Phensuximide Amobarbital Ketamine Phentermine Ascorbic acid Lidocaine Phenytoin Atropine Lorazepam Primidone Barbital Methadone Pentobarbital Benylpiperazine (BZP) 3,4-MDA Phenothiazine Bromazepam 3,4-MDEA Phenylephrine Butabarbital 3,4-MDMA Phenylpropanolamine Caffeine 4-Methoxyamphetamine Procaine 2C-B Methadone metabolite (EDDP) Protryptyline Clonazepam Methaqualone Pseudoephedrine Cocaine d-methamphetamine Ranitidine Carbamazepine Metharbital Quinine Chloroquine Mephenytoin Scopolamine Chlorpromazine Mephobarbital Secobarbital Desipramine Methsuximide Sertraline Dextromethorphan Methyl Norethindrone Temazepam Dextropropoxyphene Methyl PEMA TFMPP 5,5-Diphenylhydantoin Methylphenidate Theophylline 10,11-Dihydorcabamazepine 4-Methylprimidone THC-COOH Diazepam Methylpropylsuccinimide Triamterene Diphenhydramine Methylprylon Tetracycline Doxepin Nitrazepam Tetrahydrololine Dyphylline Nordiazepam Trimipramine Ephedrine Nordoxepin Trimethoprim Ethosuximide Normethsuximide Analgesic, Related Drugs Buprenorphine Morphine Oxycodone Codeine Morphine-3-gluc Oxymorphone Cyclobenzapine Naloxone Propoxyphene Dihydrocodeine Naltrexone Tramadol Hydrocodone Norcodeine Trazodone Hydromorphone Normorphine Venlafaxine Meperidine Table IV. Clinical Urine Specimen LC MS MS Positive Negative HEIA Positive 44 0 Negative 0 42 doses and therefore yields a much longer detection time than carisoprodol in urine, was selected. The cross-reactivity for the meprobamate metabolite is approximately 10%. Interference with unrelated drugs Commonly used drugs that are structurally unrelated to carisoprodol were assayed to determine cross-reactivity or interference with the carisoprodol antibody (Table III). Aliquots of unrelated drugs were spiked into synthetic urine at a concentration of 10,000 ng/ml. None of these compounds produced values in the assay equal to or greater than the assay sensitivity level (5 ng/ml). Interference with analgesic, related drugs Commonly used analgesic drugs that may be used in combination with carisoprodol were assayed to determine if these drugs cross-reacted or interfered with the carisoprodol HEIA (Table III). Aliquots of the drugs were spiked to synthetic urine at a concentration of 10,000 ng/ml. None of these compounds produce values in the assay equal to or greater than the assay sensitivity level (5 ng/ml). Stability To determine the preliminary product shelf life of the accelerated stability study, the Q rule technique was applied to project a preliminary shelf life for the product. This rapid technique of determining shelf life is common practice in pharmaceutical and diagnostic industries to estimate product shelf life for an accelerated stability study (13). In addition, stability studies (accelerated and real time) from previous in-house commercial HEIA kits were taken into account to establish a preliminary product shelf life. For this accelerated stability study, at the 100 ng/ml cutoff of the assay there was no decrease in assay performance when carisoprodol HEIA was stored at 25 C for 21 days, which is equivalent to at least 6 months storage of the HEIA at 5 C. A real-time stability study for this assay is ongoing. Patient urine samples Eighty-six urine specimens were donated from various laboratories. These were a mixture of positive and negative for carisoprodol and meprobamate and the confirmation results were provided from the independent facilities. Of the 86 spec- 111
5 imens, 42 were confirmed negative by LC MS MS and 44 specimens were confirmed positive. The specimens were analyzed by carisoprodol HEIA and a comparison between the HEIA and LC MS MS was carried out to evaluate the sensitivity, specificity, and accuracy of the HEIA assay. The sensitivity, specificity, and accuracy values are 100%, 100%, and 100%, respectively (Table IV). Conclusions This paper describes the validation of a highly sensitive homogeneous enzyme immunoassay capable of detecting both carisoprodol and meprobamate in urine, using either drug as a calibration standard. The recommended cutoff for carisoprodol is 100 ng/ml and the recommended cutoff for meprobamate is 500 ng/ml. The assay has an LOD of 5 ng/ml and is a reliable method of screening for carisoprodol and meprobamate in urine on a routine basis. References 1. J.K. Elenbaas. Centrally acting oral skeletal muscle relaxants. Am. J. Hosp. Pharm. 37: (1980) 2. J. Denisson, J.N. Edwards, and G.N. Volans. Meprobamate overdosage. Hum. Toxicol. 4: (1985). 3. N.C. Elder. Abuse of skeletal muscle relaxants. Am. Fam. Physician 44: (1991). 4. M. Robertson and L. Marinetti. Carisoprodol effects on human performance and behavior. Forensic Sci. Rev. 15: 1 9 (2003). 5. L.J. Farrell, S. Kerrigan, and B.K. Logan. Recommendations for toxicological investigation of drugs impaired driving. J. Forensic Sci. 52(5): (2007). 6. E.J. Cone, Y.H. Caplan, D.L. Black, T. Robert, and F. Moser. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J. Anal. Toxicol. 32: (2008). 7. Carisoprodol ELISA Product Insert. Immunalysis Corporation. Pomona, CA. 8. I.R. Miksa and R.H. Poppenga. Direct and rapid determination of baclofen (Lioresal ) and carisoprodol (Soma ) in bovine serum by liquid chromatography mass spectrometry. J. Anal. Toxicol. 27: (2003). 9. T. Matsumoto, T. Sano, T. Matsuoka, M. Aoki, Y. Maeno, and M. Nagao. Simultaneous determination of carisoprodol and acetaminophen in an attempted suicide by liquid chromatography mass spectrometry with positive electrospray ionization. J. Anal. Toxicol. 27: (2003). 10. S. Daval, D. Richard, B. Souweine, A. Eschalier, and F. Coudore. A one-step and sensitive GC MS assay for meprobamate determination in emergency situations. J. Anal. Toxicol. 30: (2006). 11. W. Skinner, D. McKemie, and S. Stanley. Quantitative determination of carisoprodol and its metabolites in equine urine and serum by liquid chromatography tandem mass spectrometry. Chromatographia 59(Suppl. 1): S61 S67 (2004). 12. D. Downey, K. Simons, K. Ota, and S. Kerrigan. Quantitative analysis of carisoprodol and meprobamate in whole blood using benzylcarbamate and deurerated meprobamate as internal standards. J. Anal. Toxicol. 33: (2009). 13. G. Anderson and M. Scott. Determination of product shelf life and activation energy for five drugs of abuse. Clin. Chem. 37: (1991). Manuscript received May 10, 2010; revision received August 20,
Morphine ELISA Kit. Catalog Number KA assays Version: 05. Intended for research use only.
Morphine ELISA Kit Catalog Number KA0935 96 assays Version: 05 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Principle of the Assay... 3 General Information...
More informationAmphetamine ELISA Kit
Amphetamine ELISA Kit Catalog Number KA0926 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the Assay...
More informationLCMS-8050 Drugs of Abuse: 113 Analytes with Polarity Switching
Liquid Chromatography Mass Spectrometry SSI-LCMS-8 LCMS-8 Drugs of Abuse: Analytes with Polarity Switching LCMS-8 Summary Seventy six analytes and their internal standards are described below. Multiple
More information1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia
NEW TESTS Please Note: Not all test codes assigned to each assay are listed in the table of contents. Please refer to the complete listing on the page numbers indicated. Test Code Test Name Effective Date
More informationA Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography
Application Note LCMS-109 A Simple and Accurate Method for the Rapid Quantitation of Drugs of Abuse in Urine Using Liquid Chromatography Time of Flight (LC-TOF) Mass Spectrometry Introduction Many clinical
More informationDrugSmartCup & DrugSmartDip Accuracy Report as produced by Ameditech, Inc.
Accuracy The accuracy of the DrugSmart Drugs of Abuse Tests was evaluated in comparison to commercially available drug screen tests. Sixty (60) negative urine samples collected from presumed non-user volunteers
More informationForensic Toxicology Scope of Testing and Detection Limits
Forensic Toxicology Scope of Testing and Detection Limits Table of Contents QUALITATIVE ANALYSES... 2 Volatile Screen by GC/FID... 2 Carbon Monoxide by Microdiffusion... 2 Ethylene Glycol by GC/MS... 2
More informationDetermination of Benzodiazepines in Oral Fluid using LC MS MS
Determination of Benzodiazepines in Oral Fluid using LC MS MS Technical Note Christine Moore 1,*, Cynthia Coulter 1, Katherine Crompton 1, and Michael Zumwalt 2 1 Immunalysis Corporation, 829 Towne Center
More informationA Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS
A Comprehensive Screening of Illicit and Pain Management Drugs from Whole Blood Using SPE and LC/MS/MS Introduction Drug analysis from whole blood is gaining popularity due to a more complete measurement
More informationFully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids
PO-CON1753E Fully Automated Online Sample Preparation and LC-MS/MS Analysis of Drugs of Abuse in Oral Fluids ASMS 2017 TP-442 Joshua F. Emory 1, Nathan DeFreitas 2, Michael Roberts 1, Manoj Tyagi 2, M.
More informationValidation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens
Validation Report for the Neogen Fentanyl Kit for ELISA Screening of Whole Blood and Urine Specimens This document describes the validation of a Neogen Fentanyl kit for the semi-quantitative analysis of
More informationValidation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS
Validation of a Benzodiazepine and Z-Drug Method Using an Agilent 6430 LC/MS/MS Application Note Forensics Authors Jason Hudson, Ph.D., James Hutchings, Ph.D., and Rebecca Wagner, Ph.D. Virginia Department
More informationYour Results are Our Priority.
Your Results are Our Priority. Enzyme Linked Immunosorbent Assay (ELISA) One year shelf life Ready to use, color coded reagents and bottles Single dilution factor Adaptable for all forensic matrices Forensic
More information1. Amphetamine (Adderall, desoxyn, Dexedrine,dextrostat, spancap, oxydess II)
Cross reactivity of various pharmaceuticals against the Drugs of Abuse Screening Panel (posted 2/3/09) The following tables are only applicable to the specific analyzer and reagents used at HRHS main lab.
More informationCDIA TM Marijuana Colloidal Gold Test Cassette (Saliva)
CDIA TM Marijuana Colloidal Gold Test Cassette (Saliva) Cat. No.: DTSJZ023 Pkg. Size: Intended Use The CDIA TM Marijuana Colloidal Gold Test Cassette (Saliva) is an immunochromatography based one step
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D Director: David J.
Drug Adherence Assessment Report Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED PRESCRIPTION FLAG ANTICIPATED
More informationAchieving Proposed Federal Concentrations using Reduced Specimen Volume for the Extraction of Amphetamines from Oral Fluid
Achieving Proposed Federal Concentrations using Reduced Specimen Volume for the Extraction of Amphetamines from Oral Fluid Christine Moore, Cynthia Coulter, and Katherine Crompton Immunalysis Corporation,
More informationORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS
ORAL FLUID AS A CHEMICAL TEST FOR THE DRE PROGRAM : HISTORY, THE FUTURE, AND PRACTICAL CONSIDERATIONS Barry K Logan PhD, DABFT National Director of Forensic Services, NMS Labs Willow Grove PA Disclaimer
More informationThe Drug Testing Process. Employer or Practice
Disclosures Clinical Professor, Jefferson Medical College BOD MROCC [Medical Review Officer Certification Council] BOD National Sleep Foundation BOD POEMS [Pennsylvania Occupational & Environmental Medicine
More informationPRINCIPLE REF ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE
SYNCHRON System(s) Chemistry Information Sheet Copyright 2010 Beckman Coulter, Inc. Opiate 300 ng REF 475024 For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by: Date PRINCIPLE INTENDED
More informationOne Source Toxicology Laboratory, 1213 Genoa Red Bluff, Pasadena, Texas 77504
Validation of Analysis of Amphetamines, Opiates, Phencyclidine, Cocaine, and Benzoylecgonine in Oral Fluids by Liquid Chromatography Tandem Mass Spectrometry Subbarao V. Kala*, Steve E. Harris, Tom D.
More informationSeptember HCMC Toxicology Transition: Additional information and Frequently Asked Questions
September 2016 HCMC Toxicology Transition: Additional information and Frequently Asked Questions Many clinicians have asked for more information about the Urine Drug Compliance Analysis (LAB8742) switch
More informationQuantitative Analysis of Opiates in Urine Using RRHT LC/MS/MS. Application. Authors. Introduction. Abstract. Forensics
Quantitative Analysis of piates in Urine Using RRHT LC/MS/MS Application Forensics Authors Sheher Mohsin Agilent Technologies, Inc. 10 N. Martingale Rd., Suite 550 Schaumburg, IL 60173 USA Yanan Yang Agilent
More informationEvaluation of the Impact of Expanding ELISA Screening in DUID Investigations. Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K.
Evaluation of the Impact of Expanding ELISA Screening in DUID Investigations Aileen Lu*, Karen S. Scott, Aya Chan-Hosokawa, and Barry K. Logan FSF Emerging Forensic Scientist Award Oral Presentation Disclosure
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: NO MEDICATION LIST PROVIDED CONSISTENT RESULTS - MEDICATION DETECTED (PARENT DRUG
More informationINTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY
INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE, MARYLAND QUARTERLY REPORT: FOURTH QUARTER, 2008 AND 2008 SUMMARY A report from the Office of Epidemiology and Planning Baltimore
More informationIntercept i2he Methamphetamine Oral Fluid Assay
Intercept i2he Methamphetamine FOR FORENSIC USE ONLY For Use with Intercept i2he Oral Fluid Collection Device 1001-0386 (65 ml Kit) INTENDED USE The Intercept i2he Methamphetamine is intended for use in
More informationOP2 PRINCIPLE REF ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE
SYNCHRON System(s) Chemistry Information Sheet Copyright 2010 Beckman Coulter, Inc. Opiate 2000 ng REF 475006 For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by: Date PRINCIPLE INTENDED
More informationStandard Operating Procedure Screening Test for Cocaine Metabolite in Urine
University of Colorado at Denver January 20, 2004 - Revision 1.50 Page 1 of 9 1 Background*: Standard Operating Procedure Screening Test for Cocaine Metabolite in Urine Cocaine (benzoylmethylecgonine)
More informationDrug Adherence Assessment Report
Prescribed Medications: Drug Adherence Assessment Report FENTANYL, OXYCODONE CONSISTENT RESULTS - REPORTED MEDICATION DETECTED (PARENT DRUG AND/OR METABOLITE) REPORTED ANTICIPATED TEST PRESCRIPTION (S)
More informationINTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY
2009 FINAL REPORT INTOXICATION DEATHS ASSOCIATED WITH DRUGS OF ABUSE OR ALCOHOL BALTIMORE CITY This report was prepared by: Dr. Jose Arbelaez, M.D. of Baltimore Substance Abuse Systems, and Ryan J. Petteway,
More informationFast and easy separation of 23 drugs of abuse. including high, stable resolution of isobaric opioids from human urine by UHPLC-MS/MS
TECHNICAL NOTE 21883 Fast and easy separation of 23 drugs of abuse including high, stable resolution of isobaric opioids from human urine by UHPLC-MS/MS Authors Kean Woodmansey 1, Jon Bardsley 1 and Stacy
More informationAlcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082
Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending
More informationLaboratory Testing to Support Pain Management: Methods, Concepts and Case Studies
Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies Frederick G. Strathmann, PhD, DABCC, (CC,TC) Medical Director, Toxicology Associate Scientific Director of MS ARUP Laboratories
More informationIntercept i2he Opiate Oral Fluid Assay
FOR FORENSIC USE ONLY For Use with Oral Fluid Collection Device 1001-0387 (65 ml Kit) INTENDED USE The is intended for use in the qualitative determination of Opiate in human oral fluid at a cutoff concentration
More informationQuantitative Analysis of Drugs of Abuse in Urine using UHPLC Coupled to Accurate Mass AxION 2 TOF Mass Spectrometer
application Note Liquid Chromatography/ Mass Spectrometry Authors Sharanya Reddy Blas Cerda PerkinElmer, Inc. Shelton, CT USA Quantitative Analysis of Drugs of Abuse in Urine using UHPLC Coupled to Accurate
More informationDetermination of 78 Banned or Controlled Racing Industry Drugs in Horse Urine Using SPE and LC-MS/MS
Determination of 78 Banned or Controlled Racing Industry Drugs in Horse Urine Using SPE and LC-MS/MS UCT Part Numbers XRDAH203 Gravity Flow XtrackT DAU 200 mg, 3 ml column SPHPHO6001-5 Select ph Buffer
More informationLC Application Note. Dangerous driver?
LC Application Note Dangerous driver? www.palsystem.com Dangerous driver? Robert M. Sears 1 ; Kenneth C. Lewis 2 ; and Kim Gamble 3 1 SC Law Enforcement Division, Columbia, SC 29221; 2 OpAns LLC, Durham
More informationUsing Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population
Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population Adam S. Ptolemy 1, Colleen Murray 2, Edward Dunn 3,
More informationUltrafast Analysis of Benzodiazepines in Urine by the Agilent RapidFire High-Throughput Triple Quadrupole Mass Spectrometry System
Ultrafast Analysis of Benzodiazepines in Urine by the Agilent RapidFire High-Throughput Triple Quadrupole Mass Spectrometry System Application Note Forensic Toxicology Authors Nikunj R. Parikh, Michelle
More informationL Abstract J. Introduction
Development and GC-MS Validation of a Highly Sensitive Recombinant G6PDH-Based Homogeneous Immunoassay for the Detection of Buprenorphine and Norbuprenorphine in Urine* Guohong Wang 1, Michael Vincent
More informationRapid and Sensitive Analysis of a 93-Compound Forensic Panel in Urine using the QTRAP /Triple Quad 4500 LC- MS/MS System
Rapid and Sensitive Analysis of a 93-Compound Forensic Panel in Urine using the QTRAP /Triple Quad 4500 LC- MS/MS System Xiang He, 1 Casey Burrows 1, Matthew Noestheden 2, Michael Jarvis, 2 Adrian Taylor,
More informationUrine Drug Testing Methods 3-5
Urine Drug Testing Methods 3-5 Type of Test Logistics Pearls Initial Screening Test: Immunoassay Confirmatory Test: Gas chromatography-mass spectrometry (GCMS) + or Liquid chromatography-mass spectrometry
More informationMETHAMPHETAMINE & AMPHETAMINE
METHAMPHETAMINE & AMPHETAMINE Enantiomers from Urine Rapid and Accurate Chiral Separation Polysaccharide Chiral Chiral LC LC Columns and SFC PHEN-RUO-49 Revision: Lux 3 µm AMP Column High Efficiency LC/MS/MS
More informationComparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis of Basic Drugs
Seyed Sadjadi, Shahana Huq, Sean Orlowicz and Laura Snow Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA Comparison of Different Whole Blood Sample Pretreatment Methods for Targeted Analysis
More informationIntercept i2he Amphetamine Oral Fluid Assay
FOR FORENSIC USE ONLY For Use with Oral Fluid Collection Device 1001-0385 (65 ml Kit) INTENDED USE The is intended for use in the qualitative determination of amphetamine in human oral fluid at a cutoff
More informationModernizing the Forensic Lab with LC-MS/MS Technology
Modernizing the Lab with LC-MS/MS Technology Innovative SCIEX Analytical Tools for the Rapid Identification of Drugs of Abuse in Samples Oscar G. Cabrices 1, Holly McCall 1, Xiang He 1, Alexandre Wang
More information[ APPLICATION NOTE ] APPLICATION BENEFITS INTRODUCTION WATERS SOLUTIONS KEYWORDS
A Comprehensive Method for the Analysis of Pain Management Drugs and Drugs of Abuse Incorporating Simplified, Rapid Mixed-Mode SPE with UPLC-MS/MS for Clinical Research Jonathan P. Danaceau, Scott Freeto,
More informationCOCAINE-QUALITATIVE IMMUNOASSAY (COC) Wedges each contain usable volumes of 23 ml of R1 reagent and 9 ml of R2 reagent.
REF 14241-4 4 x 23 ml/9 ml COCAINE-QUALITATIVE IMMUNOASSAY (COC) Wedges each contain usable volumes of 23 ml of R1 reagent and 9 ml of R2 reagent. INTENDED USE The EasyRA Cocaine (COC) reagent is intended
More informationHigh-Throughput Quantitative LC-MS/MS Analysis of 6 Opiates and 14 Benzodiazepines in Urine
High-Throughput Quantitative LC-MS/MS Analysis of and 14 Benzodiazepines in Urine Bill Yu, Kristine Van Natta, Marta Kozak, Thermo Fisher Scientific, San Jose, CA Application Note 588 Key Words Opiates,
More informationT2007 Seattle, Washington
T2007 Seattle, Washington Application of Liquid Chromatography-Mass Spectrometry with Atmospheric Pressure Chemical Ionization as a Screening Method for forty-two Date-Rape Drugs Piotr Adamowicz*, Maria
More informationOraSure Technologies, Inc. 150 Webster Street, Bethlehem, PA Phone: (USA) Fax:
OraSure Technologies, Inc. 150 Webster Street, Bethlehem, PA 18015-1389 Phone: 610-882-1820 1-800-869-3538 (USA) Fax: 610-882-1830 www.orasure.com OPIATES INTERCEPT MICRO-PLATE EIA for use with Intercept
More informationProof of Concept for Automated SPE/HPLC/MS/MS Methods to Replace Traditional Immunoassay with MS Confirmation of Driving Under the Influence Samples
Proof of Concept for Automated SPE/HPLC/MS/MS Methods to Replace Traditional Immunoassay with MS Confirmation of Driving Under the Influence Samples Robert M. Sears, Toxicology Technical Leader 1, Kenneth
More informationE XCEL LENCE JUST GOT BETTER UCT FORENSICS CLEAN SCREEN XCEL SPE COLUMNS
FORENSICS UCT E XCEL LENCE JUST GOT BETTER CLEAN SCREEN XCEL SPE COLUMNS CLEAN SCREEN XCEL COLUMNS EXTRACTION OF BASIC DRUGS AND METABOLITES FROM URINE/ BLOOD USING SPE CARTRIDGES 130mg Clean Screen Xcel
More informationValidation of an Automated Method to Remove
Shahana Wahab Huq 1, Richard Thomas 2, Agnes Cua 2, Seyed Sadjadi 1 1 Phenomenex, 411 Madrid Avenue, Torrance, CA 951 2 Precision Toxicology, 33 Bunker Hill Street, San Diego, CA 9219 Validation of an
More informationAmphetamines, Phentermine, and Designer Stimulant Quantitation Using an Agilent 6430 LC/MS/MS
Amphetamines, Phentermine, and Designer Stimulant Quantitation Using an Agilent 643 LC/MS/MS Application Note Forensics Authors Jason Hudson, Ph.D., James Hutchings, Ph.D., and Rebecca Wagner, Ph.D. Virginia
More information3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years
Drug Adherence Assessment Report CleanAssure TM (DRIED BLOOD SPOT): Detection Range see NOTES. Prescribed Medications: HYDROMORPHONE (DILAUDID, EXALGO), CYCLOBENZAPRINE (FLEXERIL), METHADONE (METHADOSE),
More informationRapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab
Application Note Clinical Research Rapid LC/TOF MS for Analytical Screening of Drugs in the Clinical Research Lab Authors Adam Barker 1,2, Frederick G. Strathmann 3, Natalie N. Rasmussen 4, and Carrie
More informationDirect Analysis of Urinary Opioids and Metabolites by Mixed-Mode µelution SPE Combined with UPLC/MS/MS for Forensic Toxicology
Direct Analysis of Urinary Opioids and Metabolites by Mixed-Mode µelution SPE Combined with UPLC/MS/MS for Forensic Toxicology Jonathan P. Danaceau, Erin E. Chambers, and Kenneth J. Fountain Waters Corporation,
More informationDate. Measurements of cocaine and cocaine metabolites are used in the diagnosis and treatment of cocaine use or overdose.
SYNCHRON System(s) Chemistry Information Sheet Copyright 2010 Beckman Coulter, Inc. Cocaine Metabolite REF 475003 For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by: Date Reviewed by: Date PRINCIPLE
More informationDETERMINATION OF CANNABINOIDS, THC AND THC-COOH, IN ORAL FLUID USING AN AGILENT 6490 TRIPLE QUADRUPOLE LC/MS
FORENSICS AND TOXICOLOGY ANALYSIS DETERMINATION OF CANNABINOIDS, THC AND THC-COOH, IN ORAL FLUID USING AN AGILENT 6490 TRIPLE QUADRUPOLE LC/MS Solutions for Your Analytical Business Markets and Applications
More informationAgilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications. dr. Jan Srbek, HPST. Page 1
Agilent Clinical LC/MS: Review of Established LC-MS QQQ Clinical Research Applications dr. Jan Srbek, HPST Page 1 Major LC-MS Clinical Applications Steroids/Endocrinology Vitamin D Testosterone, Estradiol
More informationDrugs of Abuse in Oral Fluids: Automated SPE Extraction and LC/MS/MS Determination using a Robotic Autosampler
Drugs of Abuse in Oral Fluids: Automated SPE Extraction and LC/MS/MS Determination using a Robotic Autosampler Fred D. Foster 1, John R. Stuff 1, Jacqueline A. Whitecavage 1, Edward A. Pfannkoch 1, Mark
More informationApplication Note LCMS-108 Quantitation of benzodiazepines and Z-drugs in serum with the EVOQ TM LC triple quadrupole mass spectrometer
Application Note LCMS-108 Quantitation of benzodiazepines and Z-drugs in serum with the EVOQ TM LC triple quadrupole mass spectrometer Abstract This study demonstrates a sensitive, rapid and reliable research
More informationUltra-Fast Forensic Toxicological Screening and Quantitation under 3 Minutes using SCIEX X500R QTOF System and SCIEX OS 1.
Ultra-Fast Forensic Toxicological Screening and Quantitation under 3 Minutes using SCIEX X500R QTOF System and SCIEX OS 1.0 Software Xiang He 1, Adrian M. Taylor 2, Michael Jarvis 2 and Alexandre Wang
More informationPain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX
Pain Management and Compliance Toxicology Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX Prescription Drug Abuse: A National Problem Prescription drug abuse is a growing
More informationQuantitative Analysis of Amphetamine-Type Drugs by Extractive Benzoylation and LC/MS/MS. Application. Introduction. Authors. Abstract.
Quantitative Analysis of Amphetamine-Type Drugs by Extractive Benzoylation and LC/MS/MS Application Forensics Authors Neil Campbell, B. Sc. Forensic Science Laboratory Chemistry Centre (WA) 5 Hay Street
More informationA Rapid Method for Detection of Drugs of Abuse in Blood Samples Using the Thermal Separation Probe and the 5975T LTM GC/MS
A Rapid Method for Detection of Drugs of Abuse in Blood Samples Using the Thermal Separation Probe and the 5975T LTM GC/MS Application Note Forensics Authors Suli Zhao Agilent Technologies, Inc. Shanghai
More informationAnalyze Barbiturates in Urine with Agilent 6430 LC/MS/MS and Poroshell 120 EC-C18
Analyze Barbiturates in Urine with Agilent 6 LC/MS/MS and Poroshell EC-C8 Application ote Forensic Toxicology Authors Elijah Steinbauer and Pat Friel Toxicology Laboratory at the Veterans Administration
More informationOverview. Introduction. Experimental. Cliquid Software for Routine LC/MS/MS Analysis
A Fast and Sensitive LC/MS/MS Method for the Quantification and Confirmation of 3 Benzodiazepines and Nonbenzodiazepine Hypnotics in Forensic Urine Samples Cliquid Software for Routine LC/MS/MS Analysis
More informationINTERPATH LABORATORY, INC. TEST UPDATES
EFFECTIVE DATE: February 16, 2016 INTERPATH LABORATORY, INC. TEST UPDATES Please take note of the following test updates and make the appropriate changes in your Interpath Service Manual. Feel free to
More informationA Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine
PO-CON737E A Novel Platform of On-line Sample Pre-treatment and LC/MS/MS Analysis for Screening and Quantitation of Illicit Drugs in Urine ASMS 7 WP 353 Shao Hua Chia ; Zhi Wei Edwin Ting ; Daisuke Kawakami
More informationApplication. Detection of Cannabinoids in Oral Fluid Using Inert Source GC/MS. Introduction. Authors. Abstract. Forensic Toxicology
Detection of Cannabinoids in Oral Fluid Using Inert Source GC/MS Application Forensic Toxicology Authors Christine Moore, Sumandeep Rana, and Cynthia Coulter Immunalysis Corporation 829 Towne Center Drive
More informationPrepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature. Distributed to # of Copies Distributed to # of Copies
Procedure: Status DS Prepared by Date Adopted Supersedes Procedure # Review Date Revision Date Signature Distributed to # of Copies Distributed to # of Copies PRINCIPLE: The Status DS 10 Panel (MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP)
More informationDetermination of Benzodiazepines in Urine by CE-MS/MS
Determination of Benzodiazepines in Urine by CE-MS/MS Application ote Forensic Toxicology Authors audimir Lucio do Lago Department of Fundamental Chemistry, Institute of Chemistry University of São Paulo,
More information4.5 Minute Analysis of Benzodiazepines in Urine and Whole Blood Using LC/MS/MS and an Ultra Biphenyl Column
Clinical, Forensic & Toxicology Applications 4.5 Minute Analysis of Benzodiazepines in Urine and Whole Blood Using LC/MS/MS and an Ultra Biphenyl Column By Amanda Rigdon Abstract A rapid, sensitive method
More informationQuantitative Method for Amphetamines, Phentermine, and Designer Stimulants Using an Agilent 6430 LC/MS/MS
Quantitative Method for Amphetamines, Phentermine, and Designer Stimulants Using an Agilent 6430 LC/MS/MS Application Note Forensic Toxicology Authors Jason Hudson, Ph.D., James Hutchings, Ph.D., and Rebecca
More informationPain Medication Management Program Supports Patient Outcomes and Adherence
PeaceHealth Laboratories UPDATE 2015 Revised Edition Pain Medication Management Program Supports Patient Outcomes and Adherence BENEFITS Monitors analgesic medication adherence to ensure patient safety
More informationImproving Benzodiazepine Immunoassay Sensitivity by Rapid Glucuronide Hydrolysis Technology
Improving Benzodiazepine Immunoassay Sensitivity by Rapid Glucuronide Hydrolysis Technology Pongkwan (Nikki) Sitasuwan, Margarita Marinova, and L. Andrew Lee Integrated Micro-Chromatography Systems, LLC
More informationPain Medication Management Program Monitors Patient Compliance
PeaceHealth Laboratories UPDATE 2014/15 Edition Pain Medication Management Program Monitors Patient Compliance BENEFITS Monitors analgesic medication adherence to ensure patient safety and protect your
More informationOraSure Technologies, Inc. 150 Webster Street, Bethlehem, PA Phone: (USA) Fax:
OraSure Technologies, Inc. 150 Webster Street, Bethlehem, PA 18015-1389 Phone: 610-882-1820 1-800-869-3538 (USA) Fax: 610-882-1830 www.orasure.com METHAMPHETAMINE INTERCEPT MICRO-PLATE EIA for use with
More informationToxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey
Toxicological Investigation of Drug Impaired Driving Toxicology Laboratory Survey Kayla J. Lowrie, MS, Jennifer Turri, BS, Jill Yeakel, MSFS, Barry K. Logan, PhD, DABFT, Arcadia University, 450 S. Easton
More informationScreening by immunoassay and confirmation & quantitation by GC-MS of buprenorphine and norbuprenorphine in urine, whole blood and serum
Screening by immunoassay and confirmation & quantitation by GC-MS of buprenorphine and norbuprenorphine in urine, whole blood and serum NINA KANGAS, SIRPA MYKKÄNEN, SANNA KYLLÖNEN, PÄIVI RAJALA, KARI ARINIEMI
More informationQuantitative Determination of Drugs of Abuse in Human Plasma and Serum by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup
Application Note Forensic Testing Quantitative Determination of Drugs of Abuse in Human Plasma and Serum by LC/MS/MS Using Agilent Captiva EMR Lipid Cleanup Author Limian Zhao Agilent Technologies, Inc.
More informationONLINE DAT II Results matter.
From tough questions to reliable answers. ONLINE DAT II Results matter. Patient results matter Reputations are at stake: theirs and yours. Behind every Drugs-of-Abuse Test (DAT) result is a person whose
More informationToxCup Drug Screen Cup Step-by Step Instructions
ToxCup Drug Screen Cup Step-by Step Instructions This is a preliminary screening test that detects drug-of-abuse in urine at specified detection levels. To confirm preliminary positive results, a more
More informationEffective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)
1 Policy #: 803 (PLH-803-02) Effective Date: NA Reviewed Date: 4/11/2008 Subject: URINE DRUG SCREENS Approved by: Laboratory Executive Director, Ed Hughes (electronic signature) Approved by: Laboratory
More informationEvaluation of an LC-MS/MS Research Method for the Analysis of 33 Benzodiazepines and their Metabolites
Evaluation of an LC-MS/MS Research Method for the Analysis of 33 Benzodiazepines and their Metabolites Valérie Thibert 1, Norbert Dirsch 2, Johannes Engl 2, Martin Knirsch 2 1 Thermo Fisher Scientific,
More informationFast and simultaneous analysis of ethanol metabolites and barbiturates using the QTRAP 4500 LC-MS/MS system
Fast and simultaneous analysis of ethanol metabolites and barbiturates using the QTRAP 4500 LC-MS/MS system Xiang He 1, Adrian Taylor 2 and Alexandre Wang 1 1 SCIEX, Redwood City, USA. 2 SCIEX, Concord,
More informationProduct Catalog. May We are Toxicology. Tel Toll Free Fax
Product Catalog May 2014 www.immunalysis.com We are Toxicology. Tel 909.482.0840 Toll Free 888.664.8378 Fax 909.482.0850 Comprehensive Drug Testing Solutions 21 Urine HEIA Assays 37 ELISA Assays for Multiple
More informationLaboratory Service Report
4 05/25/19 Client C702884-DLP ROCHESTER Amphetamines, Confirmation Positive Confirmed POSITIVE by LC-S/S for the following: Amphetamine = 52 ethamphetamine = 124 ethamphetamine exists in the d- and l-isomeric
More informationFigure 1. Metabolism of dextromethorphan in vivo, via cytochrome P450-2D6.
Development and Validation of ELISA and GC MS Procedures for the Quantification of Dextromethorphan and its Main Metabolite Dextrorphan in Urine and Oral Fluid Warren C. Rodrigues, Guohong Wang, Christine
More information10/16/2017. Objectives. Drug Testing Interpretation in Addiction Care. Background. Which is Nonadherent?
Objectives Drug Testing Interpretation in Addiction Care Brandi Puet, Pharm.D. Describe the difference between immunoassay and confirmatory testing. List explanations for unexpected negative or positive
More informationOneStep Methadone Urine RapiCard InstaTest. Cat. #
CORTEZ DIAGNOSTICS, INC. 23961 Craftsman Road, Suite D/E/F Calabasas, CA 91302 USA Tel: (818) 591-3030 Fax: (818) 591-8383 E-mail: onestep@rapidtest.com Web site: www.rapidtest.com See external label Σ=25
More informationAnalysis of anti-epileptic drugs in human serum using an Agilent Ultivo LC/TQ
Application Note Clinical Research Analysis of anti-epileptic drugs in human serum using an Agilent Ultivo LC/TQ Authors Jennifer Hitchcock 1, Lauren Frick 2, Peter Stone 1, and Vaughn Miller 2 1 Agilent
More informationOneStep Barbiturates Urine RapiCard InstaTest. Cat. # FOR THE QUALITATIVE ASSESSMENT OF BARBITURATE IN HUMAN URINE
CORTEZ DIAGNOSTICS, INC. 23961 Craftsman Road, Suite D/E/F Calabasas, CA 91302 USA Tel: (818) 591-3030 Fax: (818) 591-8383 E-mail: onestep@rapidtest.com Web site: www.rapidtest.com See external label Σ=25
More informationToxicology Screening of Whole Blood Extracts Using GC/Triple Quadrupole/MS
Toxicology Screening of Whole Blood Extracts Using GC/Triple Quadrupole/MS Application Note Forensic Toxicology Authors Bruce Quimby and Mike Szelewski Agilent Technologies, Inc. 2850 Centerville Road
More informationPhysician s Reference for Urine and Blood Drug Testing and Interpretation
Physician s Reference for Urine and Blood Drug Testing and Interpretation DETECTIMED PANEL Urine (test code 70195) Screen Confirmation Screen Confirmation Alcohol Ethanol Amphetamines Amphetamine Methamphetamine
More informationOraSure Technologies, Inc. 150 Webster Street, Bethlehem, PA Phone: ν (USA) ν Fax:
OraSure Technologies, Inc. 150 Webster Street, Bethlehem, PA 18015-1389 Phone: 610-882-1820 ν 1-800-869-3538 (USA) ν Fax: 610-882-1830 www.orasure.com CANNABINOIDS INTERCEPT MICRO-PLATE EIA for use with
More informationFrequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up
Frequently Asked Questions: Opiate Dependency and Methadone Maintenance Treatment program follow-up Dr. Bhushan M. Kapur Associate Professor Department of Laboratory Medicine and Pathobiology, Faculty
More information